34. Antihistamines, Pepcid & Menopause | Filling the Gaps Medicine Left Behind

Send us Fan MailIn this episode of Mohivate, Dr Mohi Sarawgee explores one of the most talked about viral health trends of 2026 so far. Women combining an antihistamine and a heartburn tablet to manage menopause symptoms. And asks the question medicine should always ask first. What does the science actually say?The episode begins with histamine. Not the allergy molecule most people think they know, but a far more versatile chemical messenger with receptors in the gut, the heart, and the brain. From H1 to H2, from mast cells to the oestrogen-histamine feedback loop, this episode unpacks the biology behind the trend with clarity and warmth.It then explores the relationship between oestrogen and histamine in perimenopause, the role of the DAO enzyme, histamine intolerance as a distinct and underrecognised condition, and why mast cell activation syndrome is not the same as menopause, even when the symptoms overlap.The honest clinical verdict follows. Including why hot flushes are driven by the neurokinin B pathway and not histamine, what fezolinetant and elinzanetant are and why the UK was the first country in the world to approve the latter, and what HRT and non-hormonal options currently offer women who are struggling.With clinical insight, personal perspective, and a keen interest in perimenopause and menopause, this episode gives a viral trend the honest conversation it deserves. REFERENCES1.PCOS renamed to PMOS, The Lancet, 12 May 2026https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext2.CNN coverage of the viral menopause trend, May 2026https://www.cnn.com/2026/05/05/health/menopause-hormones-antacids-antihistamines-wellness3.Oestrogen and histamine bidirectional relationshiphttps://pubmed.ncbi.nlm.nih.gov/22651948/4.Diamine oxidase and oestrogen regulationhttps://pubmed.ncbi.nlm.nih.gov/31234240/5.Histamine intolerance, clinical overviewhttps://pubmed.ncbi.nlm.nih.gov/30239565/6.MCAS diagnostic criteria, https://www.jacionline.org/article/S0091-6749(24)00569-4/fulltext7.KNDy neurons and neurokinin B in menopausal hot flusheshttps://pubmed.ncbi.nlm.nih.gov/21253695/8.Fezolinetant, NICE supports NHS prescribing, March 2026https://thebms.org.uk/2026/03/nice-supports-nhs-prescribing-of-fezolinetant/9.Elinzanetant, first global approval, MHRA, July 2025https://www.gov.uk/government/news/mhra-approves-elinzanetant-to-treat-moderate-to-severe-vasomotor-symptoms-hot-flushes-caused-by-menopause10.Cetirizine withdrawal rebound pruritus, FDA warning 2025https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-problems-stopping-certain-allergy-medicationsJust a gentle reminder: this episode is for information, education, and inspiration only. It’s not a substitute for your doctor’s advice. For any personal health concerns, always seek guidance from your doctor.